Forte Biosciences Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced positive results from its Phase 1b trial for FB102 in the treatment of celiac disease. The study, which involved 32 subjects, demonstrated a significant improvement for those treated with FB102 compared to the placebo group. The trial reported a 73% improvement in the Vh:Cd ratio and a 42% reduction in gluten challenge-induced gastrointestinal symptoms for FB102-treated subjects. No dropouts or severe adverse events were reported. Forte Biosciences is set to initiate a Phase 2 celiac disease trial, with a topline readout expected in 2026. The results from the Phase 1b study were discussed in a conference call hosted by Forte Biosciences, featuring Prof. Jason Tye-Din, the principal investigator of the study.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。